Cranford-based Citius Pharmaceutical appointed industry veteran Kelly Creighton as its executive vice president of chemistry, manufacturing and controls. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius’ five pipeline programs.
“With two late Phase 3 trials nearing completion, we continue to prepare the organization for commercial success,” Myron Holubiak, CEO of Citius, said in a prepared statement. “Kelly is a seasoned pharmaceutical veteran whose accomplishments include more than 50 investigational new drug submissions and 20 approved market applications spanning multiple therapeutic areas. … Kelly has been a longstanding adviser to the Citius team on all aspects of the regulatory pathway for Mino-Lok, and we anticipate a seamless transition into this newly created in-house role.”
A senior-level regulatory affairs and quality assurance expert with nearly two decades of experience in biopharmaceuticals, pharmaceuticals, advanced therapies, including gene and cellular therapies, and combination products, Creighton has provided comprehensive regulatory strategy assessments, development plans and regulatory dossiers for programs across a wide range of therapeutic areas.
Creighton joins Citius from Clinipace Worldwide, a global contract research organization, where he served as vice president of regulatory and strategic development. As head of global CMC regulatory activities for investigational products, he has led teams throughout North America, Europe and the Asia Pacific region overseeing submissions and negotiations with regulatory authorities, as well as biosafety and environmental agencies in each of these regions.
